Bormioli Pharma S.p.A. has completed its acquisition of Remy & Geiser GmbH (R&G), a German company active in the business of plastic and glass primary packaging mainly used in the pharmaceutical industry.
 
The acquisition is a significant step on the growth path that Bormioli Pharma has undertaken since December 2017, when it became an independent company owned by Triton Investment Fund.
 
R&G develops, manufactures and sells closure, dosing systems, pipette droppers and tubular glass vials. The company employs approximately 270 people and operates through 2 plants located in Germany (Schleusingen and Altenfeld).
 
“This acquisition is part of a wider development plan aimed to make of Bormioli Pharma a truly global and innovative player,” said Andrea Lodetti, chief executive officer, Bormioli Pharma. “Through this operation Bormioli Pharma reinforces its presence in the German and Northern European markets, expands its current offering with complementary products and strengthens its manufacturing footprint adding more technological capabilities.”
 
Friedrich Hillebrand, Remy & Geiser’s owner, said, “We are proud to become a part of a solid and international group like Bormioli Pharma. With this step Remy & Geiser achieves further development potential and broadens its future horizons. It is a project I strongly believe in, and I am honored to join the group as member of the board of directors.”